AI assistant
PULSE BIOSCIENCES, INC. — Director's Dealing 2024
Jun 25, 2024
32093_dirs_2024-06-24_c99b3e4b-0abb-4811-8561-7e75186ffb83.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2024-05-12
Reporting Person: Barrett Burke Thomas (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-12 | Stock Option (right to buy) | $7.45 | A | 700000 | Acquired | 2034-05-12 | Common Stock (700000) | Direct |
| 2024-05-12 | Stock Option (right to buy) | $7.45 | A | 700000 | Acquired | 2034-05-12 | Common Stock (700000) | Direct |
Footnotes
F1: The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date.
F2: The shares subject to this option are subject to five tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.